PT Kalbe Farma, Tbk

Belkins
Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. Throughout its more than 40-year history, the Company has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise with unrivalled innovation, marketing, branding, distribution, financial strength and R&D and production expertise to promote its mission to improve health for a better life.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA TECH

SAAMA LAUNCHES ACTIVE SAFETY ANALYTICS FOR PHARMA (ASAP), CO-BUILT WITH GILEAD TO TRANSFORM SAFETY SURVEILLANCE

Saama Technologies, Inc. | October 27, 2020

news image

Saama Technologies, Inc. (“Saama”), the AI clinical analytics platform company, announced today the launch of the new Active Safety Analytics for Pharma (ASAP) product. ASAP is the first validated pharmacovigilance solution to leverage the U.S. Food and Drug Administration’s (FDA) Sentinel Common Data Model and the TreeScan methodology for detecting safety signals. ASAP was co-built with Gilead Sciences, a research-based biopharmaceutical company that discovers, develops and co...

Read More

ASTELLAS PHARMA US AND ASTELLAS GLOBAL HEALTH FOUNDATION COVID-19 PANDEMIC RESPONSE

PR Newswire | April 03, 2020

news image

Astellas Pharma US, ("Astellas") and the Astellas Global Health Foundation are each expanding support for global and local communities fighting COVID-19 by providing up to $2 million of new financial assistance, in aggregate, to meet the urgent demand for resources to help patients, healthcare workers and first responders. At a national level in the United States, Astellas is preparing to help humanitarian organizations working to support the community due to the COVID-19 outbreak. Thi...

Read More

GLOBAL OXYMETAZOLINE MARKET 2020 – COMPLEX PHARMACEUTICAL, ALLERGAN, ALTAIRE PHARMACEUTICALS, HEALTH LIFE OF USA

bccourier | April 16, 2020

news image

Global Oxymetazoline Market research report delivers the analysis of the market outlook, framework, and socio-economic impacts. This report tries to covers the authenticate information of the market size, share, product footprint, revenue, and progress rate. All this information driven by primary and secondary researches, with reliable and authentic projections regarding the technical jargon. This study assesses the current landscape of the ever-evolving business sector and the present and futur...

Read More

PHARMA TECH

FUSION PHARMACEUTICALS ANNOUNCES PRESENTATION OF PRECLINICAL DATA SUPPORTING ITS FPI-1966 AND FPI-2059 TARGETED ALPHA THERAPIES

Fusion | October 23, 2021

news image

Fusion Pharmaceuticals a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data that provide further support of its FPI-1966 and FPI-2059 targeted alpha therapies at the 34th Annual European Association of Nuclear Medicine Congress. These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine target...

Read More

PHARMA TECH

Saama Technologies, Inc. | October 27, 2020

news image

SAAMA LAUNCHES ACTIVE SAFETY ANALYTICS FOR PHARMA (ASAP), CO-BUILT WITH GILEAD TO TRANSFORM SAFETY SURVEILLANCE

Saama Technologies, Inc. (“Saama”), the AI clinical analytics platform company, announced today the launch of the new Active Safety Analytics for Pharma (ASAP) product. ASAP is the first validated pharmacovigilance solution to leverage the U.S. Food and Drug Administration’s (FDA) Sentinel Common Data Model and the TreeScan methodology for detecting safety signals. ASAP was co-built with Gilead Sciences, a research-based biopharmaceutical company that discovers, develops and co...

Read More

PR Newswire | April 03, 2020

news image

ASTELLAS PHARMA US AND ASTELLAS GLOBAL HEALTH FOUNDATION COVID-19 PANDEMIC RESPONSE

Astellas Pharma US, ("Astellas") and the Astellas Global Health Foundation are each expanding support for global and local communities fighting COVID-19 by providing up to $2 million of new financial assistance, in aggregate, to meet the urgent demand for resources to help patients, healthcare workers and first responders. At a national level in the United States, Astellas is preparing to help humanitarian organizations working to support the community due to the COVID-19 outbreak. Thi...

Read More

bccourier | April 16, 2020

news image

GLOBAL OXYMETAZOLINE MARKET 2020 – COMPLEX PHARMACEUTICAL, ALLERGAN, ALTAIRE PHARMACEUTICALS, HEALTH LIFE OF USA

Global Oxymetazoline Market research report delivers the analysis of the market outlook, framework, and socio-economic impacts. This report tries to covers the authenticate information of the market size, share, product footprint, revenue, and progress rate. All this information driven by primary and secondary researches, with reliable and authentic projections regarding the technical jargon. This study assesses the current landscape of the ever-evolving business sector and the present and futur...

Read More

PHARMA TECH

Fusion | October 23, 2021

news image

FUSION PHARMACEUTICALS ANNOUNCES PRESENTATION OF PRECLINICAL DATA SUPPORTING ITS FPI-1966 AND FPI-2059 TARGETED ALPHA THERAPIES

Fusion Pharmaceuticals a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data that provide further support of its FPI-1966 and FPI-2059 targeted alpha therapies at the 34th Annual European Association of Nuclear Medicine Congress. These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine target...

Read More